PTPI
Petros Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$0.01
+20.00%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +80.5%
- EBIT
- +76.9%
- EPS
- +171.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +58.4%
- EBIT
- +73.7%
- Net income
- +113.4%
- EPS
- +53.3%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026